SCHEMBL12639427

SCHEMBL12639427

C#CC(=O)N(c1ccc(Cl)cc1)C(C(=O)NC1CCCCC1)c1cccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ ALDH1A1 P00352 7/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.50
▸ TSHR P16473 3/20 0.49
▸ USP2 O75604 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ MAPT P10636 4/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PRNP P04156 1/20 0.47
▸ POLB P06746 2/20 0.46
▸ GPX4 P36969 1/20 0.45
▸ HPGD P15428 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12639406 0.91 MEN1 (0.54) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639715 0.91 TDP1 (0.59) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639491 0.90 SMN1; SMN2 (0.54) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639502 0.90 SMN1; SMN2 (0.66) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639496 0.89 TDP1 (0.54) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639363 0.88 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639486 0.88 SMN1; SMN2 (0.54) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639465 0.87 MEN1 (0.54) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639416 0.87 SMN1; SMN2 (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL12639433 0.87 ALDH1A1 (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 — — US disclosed
US-8519188-B2 Compounds which can be used for the treatment of cancers Marc-Henry Pitty (FR) 2013-08-27 — — US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 — — US disclosed
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers CYTOMICS SYSTEMS (FR) 2011-05-05 — — US disclosed
WO-2009150248-A1 COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS CYTOMICS SYSTEMS (FR) 2009-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104162-A1 Compounds which can be used for the Treatment of Cancers VHL, CYP11B2, SLC10A1 MEN1 70/4885KMT2A 3789/4885SMN1; SMN2 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback